

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

HIGHLY SELECTIVE KAT6 INHIBITOR (SYH2059 TABLETS) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.

The Board of Directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the SYH2095 tablets (the “**Product**”), a Class 1 chemical new drug co-developed by the Group and Hangzhou Innogate Pharma Co., Ltd., has obtained approval from the U.S. Food and Drug Administration (FDA) to conduct clinical trials in the U.S.

The Product is a novel, highly selective lysine acetyltransferase 6 (“**KAT6**”) inhibitor and belongs to a class of epigenetic anticancer drugs. The Product exerts its anti-tumor effects by inhibiting the acetylation of histone lysine, blocking open chromatin, and thereby regulating the cell cycle, estrogen receptor expression, and cellular senescence pathways. It is intended for the treatment of advanced malignant tumors. Preclinical studies showed that the Product demonstrated potent and selective inhibition of KAT6, significantly suppressed tumor growth, and exhibited favourable pharmacokinetic properties and safety profile.

Currently, no drug with the same target has been approved for marketing domestically or internationally, and the Product has significant clinical development value.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 24 April 2026

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.